InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: Rogerthat1 post# 8521

Wednesday, 05/11/2016 9:08:55 AM

Wednesday, May 11, 2016 9:08:55 AM

Post# of 16911
Agreed. I bought Titan because probuphine just really made sense to me for addiction: I have some life experiences in that area that have shown time and time again the power of that disease, and the inability of human willpower to conquer it. I see now that I really couldn't see the forest from the trees. And so I have focused rather singlemindedly on efficacy and the addressable market of patients requiring 8mg of buprenorphine per day, while kind of giving a shrug to the implant technology itself. It doesn't look all that impressive after all, just a thin little polymer rod. But it revolutionizes the way drugs are delivered. For me, it really crystalized it on the conference when Sunil described it as being indistinguishable from getting "hospital level IV care."

My understanding is that the primary limitation is the size of the molecule being administered: ProNeura requires relatively "small" molecules that may rule out some drugs. However, as you said, there are a multitude of possibilities...small molecule plus issues of compliance or titration=opportunity. Schizophrenia for example (Braeburn has its own implant for schizophrenia that will have to go through rigorous testing). Titan's delivery system hopefully will be cleared by the FDA after the end of this month, so the only real question will be whether it can deliver are therapeutically significant dosage.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News